Shanghai Changzheng Hospital

This early-phase trial is testing a therapy called anti-CD70 CAR-T cells in people with advanced kidney cancer that has not responded to standard treatments. The approach involves taking a patient's own immune cells, engineering them in a lab to recognize a protein called CD70 on…

This early-stage trial tests whether combining two antibodies (anti-IGF-1R and anti-PD-1) can safely control metastatic castration-resistant prostate cancer (mCRPC) — a type that has stopped responding to hormone therapy. Seven men with advanced disease will receive the combinati…

This early-phase trial tests whether a patient's own immune cells, modified to target a protein called PSMA on prostate cancer cells, are safe and can shrink tumors or lower PSA levels. It involves 7 to 18 men with metastatic castration-resistant prostate cancer that has stopped …

This early-phase trial tests a new type of immune cell therapy (PSMA-UCAR T cells) in 3 men with advanced prostate cancer that no longer responds to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants must have me…

This study compares two surgical approaches for severe ossification of the posterior longitudinal ligament (OPLL), a condition where a ligament in the spine hardens and presses on the spinal cord. One surgery (ACAF) goes through the front of the neck to remove the hardened ligame…

This trial tests whether combining a blood test that analyzes DNA fragments (cfDNA) with MRI scans can better detect prostate cancer in men with borderline PSA levels (4–10 ng/mL). Researchers aim to build a prediction model that could reduce unnecessary biopsies. The study invol…